Session » (2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2272

Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States

9:00AM-11:00AM: Abstract Number: 2323

An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health

9:00AM-11:00AM: Abstract Number: 2283

Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness

9:00AM-11:00AM: Abstract Number: 2303

Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?

9:00AM-11:00AM: Abstract Number: 2315

Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London

9:00AM-11:00AM: Abstract Number: 2296

Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey

9:00AM-11:00AM: Abstract Number: 2290

Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model

9:00AM-11:00AM: Abstract Number: 2258

Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task

9:00AM-11:00AM: Abstract Number: 2261

Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study

9:00AM-11:00AM: Abstract Number: 2306

Changes in Rheumatology Disease Measures After Initiation of Belimumab Treatment in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2319

Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry

9:00AM-11:00AM: Abstract Number: 2307

Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization

9:00AM-11:00AM: Abstract Number: 2314

Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2266

Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception

9:00AM-11:00AM: Abstract Number: 2263

Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 2304

Disparity in Healthcare in Systemic Lupus Erythematosus: A Single-Center Study

9:00AM-11:00AM: Abstract Number: 2321

Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort

9:00AM-11:00AM: Abstract Number: 2284

Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea

9:00AM-11:00AM: Abstract Number: 2316

Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study

9:00AM-11:00AM: Abstract Number: 2317

Effect of SLE-DAS Remission on Quality of Life in Patients with Systemic Lupus Erythematosus: A Cross-sectional Validation Study

9:00AM-11:00AM: Abstract Number: 2311

Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene

9:00AM-11:00AM: Abstract Number: 2309

Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2281

Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study

9:00AM-11:00AM: Abstract Number: 2269

Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study

9:00AM-11:00AM: Abstract Number: 2267

Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2270

Factors Associated with Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Systemic Lupus Erythematosus: An International Collaborative Study

9:00AM-11:00AM: Abstract Number: 2312

Fungal Infections in Hospitalized Patients of Systemic Lupus Erythematosus: A Nationwide Cohort Analysis

9:00AM-11:00AM: Abstract Number: 2262

Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study

9:00AM-11:00AM: Abstract Number: 2322

Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State

9:00AM-11:00AM: Abstract Number: 2282

Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19

9:00AM-11:00AM: Abstract Number: 2305

Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2297

Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2292

Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?

9:00AM-11:00AM: Abstract Number: 2324

Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study

9:00AM-11:00AM: Abstract Number: 2325

Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2271

Longitudinal Changes in Type 1 & Type 2 SLE Activity

9:00AM-11:00AM: Abstract Number: 2265

Lupus Damage Index Revision – Item Generation and Reduction Phase

9:00AM-11:00AM: Abstract Number: 2275

Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody

9:00AM-11:00AM: Abstract Number: 2274

Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse

9:00AM-11:00AM: Abstract Number: 2310

Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models

9:00AM-11:00AM: Abstract Number: 2299

Medication-related Hospitalizations in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2287

Mental Health of Lupus Erythematosus Patients Managed in an Academic Safety-Net Clinic

9:00AM-11:00AM: Abstract Number: 2268

Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study

9:00AM-11:00AM: Abstract Number: 2294

Organ Damage Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)

9:00AM-11:00AM: Abstract Number: 2257

Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019)

9:00AM-11:00AM: Abstract Number: 2300

Outcomes of COVID-19 Before and During the Omicron Variant Period in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study Using the TriNetX Network

9:00AM-11:00AM: Abstract Number: 2276

Patient Reported Impact of Lupus on Quality of Life

9:00AM-11:00AM: Abstract Number: 2277

Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences

9:00AM-11:00AM: Abstract Number: 2302

Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2320

Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2273

Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine

9:00AM-11:00AM: Abstract Number: 2295

Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2278

Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry

9:00AM-11:00AM: Abstract Number: 2264

Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes

9:00AM-11:00AM: Abstract Number: 2293

Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease

9:00AM-11:00AM: Abstract Number: 2301

Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years

9:00AM-11:00AM: Abstract Number: 2260

Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 2288

Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set

9:00AM-11:00AM: Abstract Number: 2289

Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease

9:00AM-11:00AM: Abstract Number: 2298

SLE Patients Are at High Risk for Tuberculosis Infection: Data from a Lupus Center of an Endemic Country

9:00AM-11:00AM: Abstract Number: 2279

Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2286

Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach

9:00AM-11:00AM: Abstract Number: 2308

The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort

9:00AM-11:00AM: Abstract Number: 2318

The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 2259

The Effects of Systematic Lupus Erythematosus Related Cognitive Impairments on Activities of Daily Living and Life Role Participation: A Qualitative Framework Study

9:00AM-11:00AM: Abstract Number: 2280

The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2291

Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of over 10,000 Patient Results Using Lab Developed Liquid Chromatography Tandem Mass Spectrometry

9:00AM-11:00AM: Abstract Number: 2313

Utilization of Palliative Care in Hospitalized Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Analysis

9:00AM-11:00AM: Abstract Number: 2285

Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].